{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:19:20Z","timestamp":1777479560889,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Stereotactic radiotherapy (SRT) and Proton therapy (PT) are both options in the management of liver lesions. Limited clinical-dosimetric comparison are available. Moreover, dose-constraint routinely used in liver PT and SRT considers only the liver spared, while optimization strategies to limit the liver damaged are poorly reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Primary endpoint was to assess and compare liver sparing of four contemporary RT techniques. Secondary endpoints were freedom from local recurrence (FFLR), overall survival (OS), acute and late toxicity. We hypothesize that Focal Liver Reaction (FLR) is determined by a similar biologic dose. FLR was delineated on follow-up MRI. Mean C.I. was computed for all the schedules used. A so-called Fall-off Volume (FOV) was defined as the area of healthy liver (liver-PTV) receiving more than the isotoxic dose. Fall-off Volume Ratio (FOVR) was defined as ratio between FOV and PTV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>213 lesions were identified. Mean best fitting isodose (isotoxic doses) for FLR were 18Gy, 21.5 Gy and 28.5 Gy for 3, 5 and 15 fractions. Among photons, an advantage in terms of healthy liver sparing was found for Vmat FFF with 5mm jaws (<jats:italic>p<\/jats:italic>\u2009=\u20090.013) and Cyberknife (<jats:italic>p<\/jats:italic>\u2009=\u20090.03). FOV and FOVR resulted lower for PT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Three years FFLR resulted 83%. Classic Radiation induced liver disease (RILD, any grade) affected 2 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Cyberknife and V-MAT FFF with 5mm jaws spare more liver than V-MAT FF with 10\u00a0mm jaws. PT spare more liver compared to photons. FOV and FOVR allows a quantitative analysis of healthy tissue sparing performance showing also the quality of plan in terms of dose fall-off.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11547-024-01788-w","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:02:55Z","timestamp":1707753775000},"page":"497-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["High dose proton and photon-based radiation therapy for 213 liver lesions: a multi-institutional dosimetric comparison with a clinical perspective"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-3335","authenticated-orcid":false,"given":"Marco Lorenzo","family":"Bon\u00f9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Turkaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Pastorello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Frassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Toraci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Spiazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Lechiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Frittoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Grazioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Ghirardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Triggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazario","family":"Portolani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Buglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Dionisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano Maria","family":"Magrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"1788_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1788_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358\u2013380. https:\/\/doi.org\/10.1002\/hep.29086","journal-title":"Hepatology"},{"key":"1788_CR3","unstructured":"NCCN (2022) NCCN clinical practice guidelines in oncology, https:\/\/www.nccn.org\/professionals\/physician_gls (2022, Accessed 15\/04\/2022)"},{"key":"1788_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1477-2574.2010.00183.x","volume":"12","author":"RE Schwarz","year":"2010","unstructured":"Schwarz RE, Abou-Alfa GK, Geschwind JF et al (2010) Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) 12:313\u2013320. https:\/\/doi.org\/10.1111\/j.1477-2574.2010.00183.x","journal-title":"HPB (Oxford)"},{"key":"1788_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semradonc.2011.05.003","volume":"21","author":"C Guha","year":"2011","unstructured":"Guha C, Kavanagh BD (2011) Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 21:256\u2013263. https:\/\/doi.org\/10.1016\/j.semradonc.2011.05.003","journal-title":"Semin Radiat Oncol"},{"key":"1788_CR6","first-page":"200","volume":"93","author":"JA Ingold","year":"1965","unstructured":"Ingold JA, Reed GB, Kaplan HS et al (1965) Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200\u2013208","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"1788_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0360-3016(94)00418-k","volume":"31","author":"TS Lawrence","year":"1995","unstructured":"Lawrence TS, Robertson JM, Anscher MS et al (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237\u20131248. https:\/\/doi.org\/10.1016\/0360-3016(94)00418-k","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR8","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","volume":"76","author":"CC Pan","year":"2010","unstructured":"Pan CC, Kavanagh BD, Dawson LA et al (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76:S94-100. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.06.092","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR9","first-page":"597","volume":"48","author":"GB Reed Jr","year":"1966","unstructured":"Reed GB Jr, Cox AJ Jr (1966) The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 48:597\u2013611","journal-title":"Am J Pathol"},{"key":"1788_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2014.02.001","volume":"111","author":"F Dionisi","year":"2014","unstructured":"Dionisi F, Widesott L, Lorentini S et al (2014) Is there a role for proton therapy in the treatment of hepatocellular carcinoma? Syst Rev Radiother Oncol 111:1\u201310. https:\/\/doi.org\/10.1016\/j.radonc.2014.02.001","journal-title":"Syst Rev Radiother Oncol"},{"key":"1788_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","volume":"76","author":"L Potters","year":"2010","unstructured":"Potters L, Kavanagh B, Galvin JM et al (2010) American society for therapeutic radiology and oncology (ASTRO) and American college of radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76:326\u2013332. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.radonc.2014.11.033","volume":"114","author":"WX Qi","year":"2015","unstructured":"Qi WX, Fu S, Zhang Q et al (2015) Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 114:289\u2013295. https:\/\/doi.org\/10.1016\/j.radonc.2014.11.033","journal-title":"Radiother Oncol"},{"key":"1788_CR13","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1007\/s00432-020-03285-9","volume":"146","author":"C Franzese","year":"2020","unstructured":"Franzese C, Bonu ML, Comito T et al (2020) Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol 146:2289\u20132297. https:\/\/doi.org\/10.1007\/s00432-020-03285-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"1788_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jhep.2020.03.005","volume":"73","author":"N Kim","year":"2020","unstructured":"Kim N, Cheng J, Jung I et al (2020) Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol 73:121\u2013129. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.005","journal-title":"J Hepatol"},{"key":"1788_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","volume":"123","author":"RJ Klement","year":"2017","unstructured":"Klement RJ, Guckenberger M, Alheid H et al (2017) Stereotactic body radiotherapy for oligo-metastatic liver disease\u2014influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 123:227\u2013233. https:\/\/doi.org\/10.1016\/j.radonc.2017.01.013","journal-title":"Radiother Oncol"},{"key":"1788_CR16","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00432-020-03223-9","volume":"146","author":"L Nicosia","year":"2020","unstructured":"Nicosia L, Cuccia F, Mazzola R et al (2020) Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. J Cancer Res Clin Oncol 146:2351\u20132358. https:\/\/doi.org\/10.1007\/s00432-020-03223-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"1788_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2015.08.031","volume":"93","author":"JD Winter","year":"2015","unstructured":"Winter JD, Wong R, Swaminath A et al (2015) Accuracy of robotic radiosurgical liver treatment throughout the respiratory cycle. Int J Radiat Oncol Biol Phys 93:916\u2013924. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.031","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.meddos.2007.04.008","volume":"33","author":"X Wang","year":"2008","unstructured":"Wang X, Krishnan S, Zhang X et al (2008) Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim 33:259\u2013267. https:\/\/doi.org\/10.1016\/j.meddos.2007.04.008","journal-title":"Med Dosim"},{"key":"1788_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.12.019","volume":"141","author":"M Buglione","year":"2020","unstructured":"Buglione M, Jereczek-Fossa BA, Bon\u00f9 ML et al (2020) Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic\/oligoprogressive non-small cell lung cancer patients: results of a multi-institutional series of 198 patients treated with \u201ccurative\u201d intent. Lung Cancer 141:1\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.019","journal-title":"Lung Cancer"},{"key":"1788_CR20","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/s0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomized, phase 2, open-label trial. Lancet 393:2051\u20132058. https:\/\/doi.org\/10.1016\/s0140-6736(18)32487-5","journal-title":"Lancet"},{"key":"1788_CR21","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/bjc.2017.103","volume":"116","author":"L Triggiani","year":"2017","unstructured":"Triggiani L, Alongi F, Buglione M et al (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116:1520\u20131525. https:\/\/doi.org\/10.1038\/bjc.2017.103","journal-title":"Br J Cancer"},{"key":"1788_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E et al (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"1788_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3857\/roj.2016.34.1.64","volume":"34","author":"SH Jung","year":"2016","unstructured":"Jung SH, Yu JI, Park HC et al (2016) A feasibility study evaluating the relationship between dose and focal liver reaction in stereotactic ablative radiotherapy for liver cancer based on intensity change of Gd-EOB-DTPA-enhanced magnetic resonance images. Radiat Oncol J 34:64\u201375. https:\/\/doi.org\/10.3857\/roj.2016.34.1.64","journal-title":"Radiat Oncol J"},{"key":"1788_CR24","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00261-019-01901-y","volume":"44","author":"K Mastrocostas","year":"2019","unstructured":"Mastrocostas K, Jang HJ, Fischer S et al (2019) Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdom Radiol (NY) 44:1795\u20131807. https:\/\/doi.org\/10.1007\/s00261-019-01901-y","journal-title":"Abdom Radiol (NY)"},{"key":"1788_CR25","unstructured":"Kogel MJaAvd (2009) Basic clinical radiobiology 4th edition. Hodder Arnold"},{"key":"1788_CR26","unstructured":"US Department of Health and Human Services NIoH, National cancer institute. Common terminology criteria for adverse events (CTCAE) Version 5: US department of health and human services"},{"issue":"3 Suppl","key":"1788_CR27","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092.PMID:20171524;PMCID:PMC4388033","volume":"76","author":"CC Pan","year":"2010","unstructured":"Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76(3 Suppl):S94-100. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.06.092.PMID:20171524;PMCID:PMC4388033","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.phro.2018.11.004","volume":"8","author":"WT Arscott","year":"2018","unstructured":"Arscott WT, Thompson RF, Yin L et al (2018) Stereotactic body proton therapy for liver tumors: dosimetric advantages and their radiobiological and clinical implications. Phys Imaging Radiat Oncol 8:17\u201322. https:\/\/doi.org\/10.1016\/j.phro.2018.11.004","journal-title":"Phys Imaging Radiat Oncol"},{"key":"1788_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13014-020-01605-4","volume":"15","author":"JY Cheng","year":"2020","unstructured":"Cheng JY, Liu CM, Wang YM et al (2020) Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. Radiat Oncol 15:159. https:\/\/doi.org\/10.1186\/s13014-020-01605-4","journal-title":"Radiat Oncol"},{"key":"1788_CR30","doi-asserted-by":"publisher","first-page":"153303382098041","DOI":"10.1177\/1533033820980412","volume":"19","author":"L Cozzi","year":"2020","unstructured":"Cozzi L, Comito T, Loi M et al (2020) The potential role of intensity-modulated proton therapy in hepatic carcinoma in mitigating the risk of dose de-escalation. Technol Cancer Res Treat 19:1533033820980412. https:\/\/doi.org\/10.1177\/1533033820980412","journal-title":"Technol Cancer Res Treat"},{"key":"1788_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00066-021-01854-6","volume":"198","author":"J Sun","year":"2022","unstructured":"Sun J, Wang Z, Sheng Y et al (2022) Indications of IMRT, PRT and CIRT for HCC from comparisons of dosimetry and normal tissue complication possibility. Strahlenther Onkol 198:361\u2013369. https:\/\/doi.org\/10.1007\/s00066-021-01854-6","journal-title":"Strahlenther Onkol"},{"key":"1788_CR32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.21037\/jgo.2019.08.03","volume":"10","author":"S Hasan","year":"2019","unstructured":"Hasan S, Abel S, Verma V et al (2019) Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation. J Gastrointest Oncol 10:999\u20131009. https:\/\/doi.org\/10.21037\/jgo.2019.08.03","journal-title":"J Gastrointest Oncol"},{"key":"1788_CR33","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3109\/0284186x.2015.1009637","volume":"54","author":"JY Kim","year":"2015","unstructured":"Kim JY, Lim YK, Kim TH et al (2015) Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. Acta Oncol 54:1827\u20131832. https:\/\/doi.org\/10.3109\/0284186x.2015.1009637","journal-title":"Acta Oncol"},{"key":"1788_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1748-717x-8-48","volume":"8","author":"C Toramatsu","year":"2013","unstructured":"Toramatsu C, Katoh N, Shimizu S et al (2013) What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy. Radiat Oncol 8:48. https:\/\/doi.org\/10.1186\/1748-717x-8-48","journal-title":"Radiat Oncol"},{"key":"1788_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.prro.2015.01.004","volume":"5","author":"SJ Gandhi","year":"2015","unstructured":"Gandhi SJ, Liang X, Ding X et al (2015) Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: photons versus protons. Pract Radiat Oncol 5:209\u2013218. https:\/\/doi.org\/10.1016\/j.prro.2015.01.004","journal-title":"Pract Radiat Oncol"},{"key":"1788_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semradonc.2017.02.001","volume":"27","author":"EL Pollom","year":"2017","unstructured":"Pollom EL, Chin AL, Diehn M et al (2017) Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol 27:197\u2013208. https:\/\/doi.org\/10.1016\/j.semradonc.2017.02.001","journal-title":"Semin Radiat Oncol"},{"key":"1788_CR37","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1002\/cncr.25997","volume":"117","author":"DT Chang","year":"2011","unstructured":"Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060\u20134069. https:\/\/doi.org\/10.1002\/cncr.25997","journal-title":"Cancer"},{"key":"1788_CR38","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","volume":"99","author":"JH Joo","year":"2017","unstructured":"Joo JH, Park JH, Kim JC et al (2017) Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Radiat Oncol Biol Phys 99:876\u2013883. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.07.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1788_CR39","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1002\/cncr.29878","volume":"122","author":"CH Crane","year":"2016","unstructured":"Crane CH, Koay EJ (2016) Solutions that enable ablative radiotherapy for large liver tumors: fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer 122:1974\u20131986. https:\/\/doi.org\/10.1002\/cncr.29878","journal-title":"Cancer"},{"key":"1788_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/radiation3020009","volume":"3","author":"ML Bon\u00f9","year":"2023","unstructured":"Bon\u00f9 ML, Pedersoli G, Balduzzi J, Cefaratti M, Mataj E, Cossali G, Granello L, Singh N, Morelli V, Tomasini D, Frassine F, Vitali P, Terraneo F, Triggiani L, Buglione M, Magrini SM (2023) Stereotactic radiotherapy for critically located pancreatic and biliary targets: a review on simultaneous integrated protection and other dose-painting strategies to minimize dose to critical organs at risk. Radiation 3:98\u2013109. https:\/\/doi.org\/10.3390\/radiation3020009","journal-title":"Radiation"},{"key":"1788_CR41","unstructured":"Oncology NRG (2022) National Cancer, I. Radiation therapy with protons or photons in treating patients with liver cancer. 579 Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03186898 (Accessed on 27-07-2022)"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-024-01788-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-024-01788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:23:20Z","timestamp":1710505400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-024-01788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s11547-024-01788-w","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"29 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical committee approved such multi-institutional analysis. Practice number 5900.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"At the time of treatment, patients signed informed consent including the possibility to use anonymized data for study purpose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participation"}}]}}